Author

Neena Kennedy

Observed name: N. Kennedy

Institutions: University of Washington, Fred Hutch Cancer Center

Observed institutions: City Of Hope National Medical Center, University of Washington, The Alfred Hospital, Fred Hutch Cancer Center, City of Hope, Monash University

OpenAlex ID: A5068340630

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

2017 · A.F. Herrera, J. Palmer, et al. · Annals of Oncology · 61

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

2023 · Matthew Mei, Lu Chen, et al. · Blood · 44

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

2022 · Alex F Herrera, Lu Chen, et al. · The Lancet Haematology · 41

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

2019 · Alex F. Herrera, Lu Chen, et al. · Blood · 22

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

2023 · James Godfrey, Matthew Mei, et al. · Haematologica · 21

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

2020 · Alex F. Herrera, Lu Chen, et al. · Blood · 20

Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade

2021 · Alex F. Herrera, Lu Chen, et al. · Blood · 2

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma

2025 · Carrie Ho, Neena Kennedy, et al. · Clinical Lymphoma Myeloma & Leukemia

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

2024 · Carrie I Ho, Neena Kennedy, et al. · Blood

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

2024 · Jennifer J. Huang, Laura Samples, et al. · Blood

LEOPARD: A Phase II Study of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone for Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

2015 · A. Kalff, N. Kennedy, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 11

Citation count: 211

H-index: 6

I10-index: 6